GSK Lupus Treatment Approved for Pediatric Patients by U.S. FDA
28 July 2022 - 4:26AM
Dow Jones News
By Stephen Nakrosis
GSK PLC on Wednesday said the U.S. Food and Drug Administration
has approved Benlysta to treat children with active lupus
nephritis.
GSK said Benlysta, or belimumab, was approved to treat children
age 5 to 17 with active lupus nephritis who are receiving standard
therapy. The company said this is the first FDA-approved treatment
for pediatric LN.
GSK also said "the approval extends the current indication in
the U.S. to include both lupus and active LN for the intravenous
formulation in the pediatric patient population."
The U.S. National Institutes of Health said lupus nephritis is a
disease affecting the kidneys. In children who have lupus, eight
out of 10 will have kidney disease, the NIH said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 27, 2022 14:11 ET (18:11 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
